menu
    • menu

    Company profile for BlackThorn Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BlackThorn Therapeutics is a clinical-stage biopharmaceutical company that uses a novel and robust approach (INFORM™) to link behavioral deficits with brain physiology to discover and develop targeted treatments for neurobehavioral disorders. We envision a future where patients with neurobehavioral disorders are quickly recognized, accurately diagnosed and effectively treated.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BlackThorn TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    780 Brannan Street San Francisco, CA 94103
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.blackthornrx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/blackthorn-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/BlackThornRX

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BlackThorn Advances Phase 2 Clinical Development for Selective KOR Antagonist
    BlackThorn Advances Phase 2 Clinical Development for Selective KOR Antagonist

    23 Jan 2020

    // BIO SPACE

    https://www.biospace.com/article/releases/blackthorn-therapeutics-advances-phase-2-clinical-development-for-selective-kor-antagonist-btrx-140-in-neuropsychiatric-disorders/

    BIO SPACE
    23 Jan 2020
    Share Share
    Polaris Partners — maps $400M for ninth fund
    Polaris Partners — maps $400M for ninth fund

    20 Jun 2019

    // Natalie Grover ENDPTS

    https://endpts.com/bob-langers-first-port-of-call-polaris-partners-maps-400m-for-ninth-fund/

    Natalie Grover ENDPTS
    20 Jun 2019
    Share Share
    BlackThorn bags $76M to push targeted treatments for brain disorders
    BlackThorn bags $76M to push targeted treatments for brain disorders

    13 Jun 2019

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/blackthorn-bags-76m-to-push-targeted-treatments-for-brain-disorders

    Amirah Al Idrus FIERCE BIOTECH
    13 Jun 2019
    Share Share
    BlackThorn Announces Positive Ph 1 Results KOR Antagonist, BTRX-335140
    BlackThorn Announces Positive Ph 1 Results KOR Antagonist, BTRX-335140

    01 Apr 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20190401005191/en/BlackThorn-Therapeutics-Announces-Positive-Phase-1-Results/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESSWIRE
    01 Apr 2019
    Share Share
    BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer
    BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer

    08 Nov 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20181105005261/en/BlackThorn-Therapeutics-Names-Bill-Martin-Ph.D.-President

    BUSINESSWIRE
    08 Nov 2018
    Share Share
    Biomatics raises $300M for healthcare fund, recruits biopharma veterans
    Biomatics raises $300M for healthcare fund, recruits biopharma veterans

    08 Nov 2018

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/biomatics-raises-300m-healthcare-fund-recruits-biopharma-vets

    Amirah Al Idrus FIERCE BIOTECH
    08 Nov 2018
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search